Akers Biosciences Inc (NASDAQ:AKER) was the recipient of a large drop in short interest in November. As of November 29th, there was short interest totalling 53,000 shares, a drop of 93.9% from the November 14th total of 875,400 shares. Approximately 10.2% of the shares of the stock are short sold. Based on an average trading volume of 41,900 shares, the short-interest ratio is presently 1.3 days.
Separately, ValuEngine cut Akers Biosciences from a “hold” rating to a “sell” rating in a report on Monday, November 25th.
NASDAQ:AKER opened at $3.11 on Friday. The business’s 50-day moving average price is $2.04 and its two-hundred day moving average price is $0.86. Akers Biosciences has a twelve month low of $2.67 and a twelve month high of $36.96.
About Akers Biosciences
Akers Biosciences, Inc, together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness.
Featured Story: Buyback For Investors Defined
Receive News & Ratings for Akers Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.